Bionical Emas
- Company typePrivate
- Founded1998
- HeadquartersWillington, United Kingdom
- Headcount251–500
- GTM typeB2B
- OfferingServices
Bionical Emas firmographics
Firmographics- Name
- Bionical Emas
- Legal name
- Bionical Emas
- Website
- https://bionicalemas.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Bionical Emas industry classification
Industry- Product category
- Pharmaceutical Services
- NAICS
- Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent) (HLAGAKAO)
- akta.pro secondary industry
- Biologics & Biosimilars Distributors (HLAIAJAH)
Keywords
Where Bionical Emas is headquartered
LocationHeadquarters
- HQ city
- Willington
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Bionical Emas business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations
Bionical Emas product offering
Product offeringCore offering
Bionical Emas provides early access programs, research, case studies, project management, clinical trial supply, and development services to pharmaceutical and biotech clients. The company also acts as a specialty pharmaceutical distributor, handling distribution and access programs for drugs such as Daraxonrasib that have received regulatory designations including FDA Breakthrough Therapy and Orphan Drug Designations.
Differentiator
Problem solved
Functional benefit
Products and services
- Daraxonrasib Distribution Services Bionical Emas serves as a pharmaceutical distributor and access-program partner for specialty drugs such as Daraxonrasib, handling distribution for products that have received FDA Breakthrough Therapy and Orphan Drug Designations on behalf of the manufacturer.
- Early Access Programs Programs that enable patients to gain access to investigational or newly designated therapeutics before or alongside broader market availability, offered to pharmaceutical and biotech manufacturers.
- Clinical Trial Supply Supply chain and logistics management for investigational products used in clinical trials, supporting pharma and biotech sponsors.
- Research and Case Studies Research deliverables and case study support provided as part of Bionical Emas' pharmaceutical services offering to drug developers and manufacturers.
- Project Management and Development Services Project management and drug development support services delivered to pharmaceutical and biotech clients as part of Bionical Emas' service portfolio.
Companies that use Bionical Emas
Customer profileIdeal customer profiles1 record
Bionical Emas technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Bionical Emas partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Revolution MedicinescoreRevolution Medicines is the manufacturer of Daraxonrasib, a drug granted Breakthrough Therapy and Orphan Drug Designations by the FDA. Bionical Emas serves as the distributor for this drug. However, as of June 2026, the manufacturer and Bionical Emas have not released the drug to the market, citing distribution problems, despite the FDA authorizing an Expanded Access Program in May 2026.
Recent moves3 records
Expansion highlights3 records
Bionical Emas competitors and assessment
Company assessmentDirect peers
- Clinigen Group: UK-headquartered pharma services firm best known for its early access programs and named-patient supply business, mirroring Bionical Emas's core service mix and geographic base.
- Almac Group: Northern Ireland-based pharmaceutical services provider covering clinical trial supply, distribution, and drug development services — directly comparable in scope and customer type to Bionical Emas.
- Marken (UPS Healthcare): Specialty logistics and clinical trial supply provider now part of UPS Healthcare, competing head-on with Bionical Emas for time-sensitive pharma distribution and IMP supply contracts.
- World Courier (Cencora): Specialty courier focused on clinical trial materials, biopharmaceutical, and cell-and-gene therapy logistics; directly competitive with Bionical Emas's clinical trial supply line.
- Myonex: Clinical trial supply and comparator sourcing specialist serving pharma and CRO clients with a similar outsourced-supply service model to Bionical Emas.
- Ancillare: US-headquartered clinical trial supply and depot-network operator delivering the same kind of sponsor-side IMP supply and ancillary services Bionical Emas provides.
Broad incumbents
- Catalent: Large-scale global CDMO and pharma services provider whose clinical supply and specialty distribution capabilities overlap with — but extend well beyond — Bionical Emas's offerings.
- IQVIA: Full-service global CRO offering clinical trial supply, real-world evidence, and commercialization services; broad incumbent whose supply services compete with Bionical Emas for sponsor budgets.
- PCI Pharma Services: Global pharma services platform providing development, clinical trial supply, and commercial packaging; broader portfolio than Bionical Emas but competes in the same outsourced supply categories.
- Fisher Clinical Services (Thermo Fisher Scientific): Trial supply, packaging, and distribution arm of Thermo Fisher Scientific; serves the same sponsor base as Bionical Emas with a much larger global footprint.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks3 records
Key highlights4 records
Customer concentration
Bionical Emas social profiles
Digital presenceBionical Emas financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bionical Emas leadership team
Management profileNumber of profiles
Bionical Emas funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bionical Emas M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bionical Emas
What does Bionical Emas do?
Bionical Emas provides early access programs, research, case studies, project management, clinical trial supply, and development services to pharmaceutical and biotech clients. The company also acts as a specialty pharmaceutical distributor, handling distribution and access programs for drugs such as Daraxonrasib that have received regulatory designations including FDA Breakthrough Therapy and Orphan Drug Designations.
Is Bionical Emas a public or private company?
Bionical Emas is a private company. It is classified as unknown and is currently operating.
When was Bionical Emas founded?
Bionical Emas was founded in 1998. It employs 251 to 500 people.
Where is Bionical Emas based?
Bionical Emas is headquartered in Willington, United Kingdom, in the Europe region.
Who are Bionical Emas's main competitors?
Direct peers on record are Clinigen Group, Almac Group, Marken (UPS Healthcare), World Courier (Cencora), Myonex and Ancillare. Broad incumbents are Catalent, IQVIA, PCI Pharma Services and Fisher Clinical Services (Thermo Fisher Scientific).
Does Bionical Emas have an API?
No public API is recorded for Bionical Emas.
What industry is Bionical Emas in?
Bionical Emas's product category is Pharmaceutical Services. Its primary akta.pro industry code is HLAGAKAO, Third-Party/Outsourced Quality & Responsible Person Services (EU QP/RP, US Agent), with a secondary code of HLAIAJAH, Biologics & Biosimilars Distributors. Its NAICS code is 54171 and its SIC code is 8731.